Tower Research Capital (TRC)’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-3,453
| Closed | -$13.5K | – | 6398 |
|
|
2023
Q3 | $13.5K | Buy |
3,453
+135
| +4% | +$921 | ﹤0.01% | 3777 |
|
|
2023
Q2 | $10.8K | Buy |
3,318
+1,702
| +105% | +$5.06K | ﹤0.01% | 4062 |
|
|
2023
Q1 | $6K | Buy |
1,616
+1,350
| +508% | +$20.8K | ﹤0.01% | 4916 |
|
|
2022
Q4 | $9K | Buy |
266
+2
| +0.8% | +$79 | ﹤0.01% | 4336 |
|
|
2022
Q3 | $11K | Sell |
264
-34
| -11% | -$1.55K | ﹤0.01% | 4495 |
|
|
2022
Q2 | $13K | Buy |
298
+155
| +108% | +$7.18K | ﹤0.01% | 4250 |
|
|
2022
Q1 | $10K | Sell |
143
-191
| -57% | -$15.9K | ﹤0.01% | 4396 |
|
|
2021
Q4 | $40K | Buy |
334
+106
| +46% | +$17.9K | ﹤0.01% | 2959 |
|
|
2021
Q3 | $32K | Buy |
228
+109
| +92% | +$21.6K | ﹤0.01% | 3333 |
|
|
2021
Q2 | $33K | Buy |
119
+23
| +24% | +$5.8K | ﹤0.01% | 3406 |
|
|
2021
Q1 | $21K | Sell |
96
-75
| -44% | -$20.7K | ﹤0.01% | 3862 |
|
|
2020
Q4 | $41K | Sell |
171
-668
| -80% | -$82.6K | ﹤0.01% | 3312 |
|
|
2020
Q3 | $88K | Buy |
839
+689
| +459% | +$62.8K | ﹤0.01% | 3243 |
|
|
2020
Q2 | $15K | Buy |
150
+120
| +400% | +$10.5K | ﹤0.01% | 3840 |
|
|
2020
Q1 | $2K | Sell |
30
-56
| -65% | -$5.33K | ﹤0.01% | 2678 |
|
|
2019
Q4 | $7K | Sell |
86
-117
| -58% | -$13.1K | ﹤0.01% | 2556 |
|
|
2019
Q3 | $24K | Buy |
203
+198
| +3,960% | +$27.2K | ﹤0.01% | 2352 |
|
|
2019
Q2 | $1K | Sell |
5
-233
| -98% | -$37.7K | ﹤0.01% | 3524 |
|
|
2019
Q1 | $38K | Buy |
238
+134
| +129% | +$26.5K | ﹤0.01% | 1914 |
|
|
2018
Q4 | $27K | Sell |
104
-93
| -47% | -$18.7K | ﹤0.01% | 1722 |
|
|
2018
Q3 | $48K | Buy |
197
+111
| +129% | +$29K | ﹤0.01% | 1794 |
|
|
2018
Q2 | $20K | Buy |
+86
| New | +$25.1K | ﹤0.01% | 2445 |
|
Other funds holding EVLO
Tower Research Capital (TRC)'s EVLO Position: Q4 2023 in Review
Tower Research Capital (TRC) sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 3,453 shares — an estimated $13.5K sold.
Tower Research Capital (TRC) first reported a position in EVLO in Q2 2018 and held it in 22 quarters. The position peaked at $88K in Q3 2020. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.
- Tower Research Capital (TRC) reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 3,453 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $13.5K.
- Tower Research Capital (TRC) first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
- Tower Research Capital (TRC)'s Evelo Biosciences, Inc. Common Stock position peaked at $88K in Q3 2020.
- 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2023, filed 13 Feb 2024.